Payment overview · 2025
General Payments
$641.07
20 reported records · 10 companies
Healthcare provider profile · identity verified
Leonard Timpone, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · FRANKLIN SQUARE, NY · NPI 1255375093
Verified facts
What the public records show
CMS Open Payments records show Leonard Timpone, M.D. received $641.07 in general payments during 2025 across 20 reported records.
Amgen Inc. accounted for 26.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 297 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 297 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $168.84 | 26.3% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $119.23 | 18.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $78.58 | 12.3% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $70.94 | 11.1% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $66.50 | 10.4% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $44.95 | 7.0% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $28.42 | 4.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $24.82 | 3.9% | 1 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $22.96 | 3.6% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.83 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $641.07 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $168.84 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $78.58 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $66.50 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $55.23 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $28.42 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $24.82 | 1 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $22.96 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $22.96 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $22.96 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.62 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.83 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.62 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $13.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 29 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
29 | 14 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
297 | 64 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
29 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
297 | 64 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 769 | 254 |
| Amlodipine Besylate | Amlodipine Besylate | 623 | 177 |
| Losartan Potassium | Losartan Potassium | 421 | 113 |
| Levothyroxine Sodium | Levothyroxine Sodium | 410 | 102 |
| Metoprolol Succinate | Metoprolol Succinate | 364 | 117 |
| Sertraline Hcl | Sertraline Hcl | 354 | 44 |
| Famotidine | Famotidine | 323 | 72 |
| Metformin Hcl | Metformin Hcl | 319 | 92 |
| Eliquis | Apixaban | 297 | 64 |
| Simvastatin | Simvastatin | 286 | 81 |
| Pantoprazole Sodium | Pantoprazole Sodium | 245 | 121 |
| Furosemide | Furosemide | 244 | 67 |
| Lisinopril | Lisinopril | 211 | 64 |
| Gabapentin | Gabapentin | 210 | 67 |
| Alprazolam | Alprazolam | 196 | 53 |
| Metoprolol Tartrate | Metoprolol Tartrate | 171 | 50 |
| Hydralazine Hcl | Hydralazine Hcl | 165 | 48 |
| Trazodone Hcl | Trazodone Hcl | 157 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 144 | 45 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 138 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 138 | 52 |
| Escitalopram Oxalate | Escitalopram Oxalate | 135 | 24 |
| Allopurinol | Allopurinol | 133 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 118 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 111 | 38 |
| Warfarin Sodium | Warfarin Sodium | 108 | suppressed |
| Januvia | Sitagliptin Phosphate | 98 | 19 |
| Levetiracetam | Levetiracetam | 95 | 17 |
| Omeprazole | Omeprazole | 95 | 34 |
| Mirtazapine | Mirtazapine | 92 | 30 |
| Latanoprost | Latanoprost | 88 | 15 |
| Atenolol | Atenolol | 87 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 85 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 81 | 38 |
| Lorazepam | Lorazepam | 80 | 19 |
| Donepezil Hcl | Donepezil Hcl | 77 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 73 | 40 |
| Xarelto | Rivaroxaban | 71 | 19 |
| Tramadol Hcl | Tramadol Hcl | 70 | 26 |
| Carvedilol | Carvedilol | 69 | 34 |
| Paroxetine Hcl | Paroxetine Hcl | 64 | suppressed |
| Potassium Chloride | Potassium Chloride | 64 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 62 | 31 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 62 | 17 |
| Memantine Hcl | Memantine Hcl | 60 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 59 | 13 |
| Enalapril Maleate | Enalapril Maleate | 59 | 19 |
| Finasteride | Finasteride | 59 | 23 |
| Tresiba Flextouch U-100 | Insulin Degludec | 58 | suppressed |
| Glimepiride | Glimepiride | 57 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | 19 |
| Meclizine Hcl | Meclizine Hcl | 53 | 23 |
| Repaglinide | Repaglinide | 52 | 14 |
| Montelukast Sodium | Montelukast Sodium | 51 | 18 |
| Admelog Solostar | Insulin Lispro | 50 | 11 |
| Azithromycin | Azithromycin | 49 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 47 | 29 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 17 |
| Buspirone Hcl | Buspirone Hcl | 44 | 12 |
| Glipizide | Glipizide | 44 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 44 | 12 |
| Midodrine Hcl | Midodrine Hcl | 43 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 42 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 42 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 19 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 41 | suppressed |
| Synthroid | Levothyroxine Sodium | 40 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | suppressed |
| Diazepam | Diazepam | 38 | suppressed |
| Naproxen | Naproxen | 38 | 27 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | suppressed |
| Nystatin | Nystatin | 37 | 17 |
| Ramipril | Ramipril | 34 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 33 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 33 | 13 |
| Spironolactone | Spironolactone | 33 | 16 |
| Donepezil Hcl Odt | Donepezil Hcl | 32 | suppressed |
| Lacosamide | Lacosamide | 32 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 32 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | suppressed |
| Digoxin | Digoxin | 31 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 31 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | 14 |
| Ezetimibe | Ezetimibe | 30 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 29 | suppressed |
| Jardiance | Empagliflozin | 29 | 14 |
| Prednisone | Prednisone | 29 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 24 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 28 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 28 | 14 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Meropenem | Meropenem | 27 | suppressed |
| Olanzapine | Olanzapine | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Folic Acid | Folic Acid | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Phenobarbital | Phenobarbital | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 19 |
| Lovastatin | Lovastatin | 22 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 22 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 22 | 19 |
| Risperidone | Risperidone | 22 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Clonazepam | Clonazepam | 20 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | 13 |
| Ozempic | Semaglutide | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Cephalexin | Cephalexin | 19 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | 13 |
| Silver Sulfadiazine | Silver Sulfadiazine | 19 | 15 |
| Valsartan | Valsartan | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Dextrose In Water | Dextrose 5 % In Water | 16 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Clonidine | Clonidine | 15 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 15 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Anastrozole | Anastrozole | 14 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Celecoxib | Celecoxib | 14 | 13 |
| Hydrocortisone | Hydrocortisone | 14 | 11 |
| Linzess | Linaclotide | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Dextrose 5%-0.9% Nacl | Dextrose 5 % And 0.9 % Nacl | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Meloxicam | Meloxicam | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Dexamethasone | Dexamethasone | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Lumigan | Bimatoprost | 12 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 11 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $641.07 · 20 records | Amgen Inc. | ABRYSVO, COMIRNATY, GLYCATE, JARDIANCE, Leqembi, MOUNJARO, NURTEC ODT, Ozempic, PAXLOVID, PREVNAR 20, RELTONE 200 MG, RELTONE 400 MG, REPATHA, REXULTI, XIFAXAN, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error